The high expressions of GM-CSF in CCA and increased GM-CSFRα-expressed ICI seemed to benefit CCA patients, particularly the worse prognostic subtype, the non-papillary one, demonstrated by longer survival times (Zen et al., 2006). The gene discussed is CSF2; the disease is cholangiocarcinoma.